The license agreement with the NRC grants Appili exclusive worldwide rights to develop and commercialize this tularemia vaccine.
ATI-1701 is based on research led by Dr. Wayne Conlan at the NRC. Conlan's team used genetic engineering to disable a previously virulent strain of F. tularensis and develop a live attenuated vaccine. Their research showed the genetically modified bacterium induced a strong immune response that triggers a protective immune response to F. tularensis.
Some of the development work for the vaccine is being funded by the Defense Threat Reduction Agency, part of the US Department of Defense, which recently announced a USD6.2 m, 5-year program to develop a tularemia vaccine.
Appili will conduct the preclinical and clinical testing required by the FDA to evaluate the safety of the ATI-1701 vaccine and to ensure it offers the desired protection against the bacteria for humans.
Appili is dedicated to identifying, acquiring, and advancing novel therapeutics for infectious disease.
Its pipeline includes three anti-infective programs: ATI-1501, a novel taste-masking technology applied in an oral suspension for the treatment for anaerobic infections, ATI-1503, a novel antibiotic targeting drug-resistant Gram-negative infections, and ATI-1701, a vaccine reducing the threat of tularemia bioterrorism.
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100